Fouad Fawzy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fouad Fawzy has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Oraby
Suez Canal University, Ismailia, Egypt
2 shared publications - Hesham Salah El Din Taha
Department of Cardiology Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications - Hossam Kandil
Department of Cardiology, Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications - Hossam Mahrous
Department of Cardiology, Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications - Juliette Bahgat
Department of Cardiology, Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications - Magdy Elsharkawy
Department of Nephrology, Ain-Shams University, Cairo, Egypt
2 shared publications
Latest Publications
- Open Access
- 20 December 2021
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 73 (1) , 1-10
Egyptian practical guidance in hypertriglyceridemia management 2021
Hypertriglyceridemia (HTG) is a very common, yet underappreciated problem in clinical practice. Elevated triglyceride (TG) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD) risk. Furthermore, severe HTG may lead to acute pancreatitis. Although LDL-guided statin therapy has improved ASCVD outcomes, residual risk remains. Recent trials have demonstrated that management of high TG levels, in patients already on statin therapy, reduces the rate of major vascular events. Few guidelines were issued, providing important recommendations for HTG management strategies. The goal of treatment is to reduce the risk of ASCVD and acute pancreatitis. The management stands on lifestyle modification, detection of secondary causes of HTG and pharmacological therapy, when indicated. In this guidance we review the causes and classification of HTG and summarize the current methods for risk estimation, diagnosis and treatment. The present guidance provides a focused update on the management of HTG, outlined in a simple user-friendly format, with an emphasis on the latest available data.
- 20 December 2021
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 73 (1) , 1-10
Open AccessEgyptian practical guidance in hypertriglyceridemia management 2021
Hypertriglyceridemia (HTG) is a very common, yet underappreciated problem in clinical practice. Elevated triglyceride (TG) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD) risk. Furthermore, severe HTG may lead to acute pancreatitis. Although LDL-guided statin therapy has improved ASCVD outcomes, residual risk remains. Recent trials have demonstrated that management of high TG levels, in patients already on statin therapy, reduces the rate of major vascular events. Few guidelines were issued, providing important recommendations for HTG management strategies. The goal of treatment is to reduce the risk of ASCVD and acute pancreatitis. The management stands on lifestyle modification, detection of secondary causes of HTG and pharmacological therapy, when indicated. In this guidance we review the causes and classification of HTG and summarize the current methods for risk estimation, diagnosis and treatment. The present guidance provides a focused update on the management of HTG, outlined in a simple user-friendly format, with an emphasis on the latest available data.
- Open Access
- 23 February 2021
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 73 (1) , 1-8
Egyptian practical guidance in lipid management 2020
Background: Numerous epidemiological investigations and randomized clinical studies have determined that dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Consequently, the management of serum cholesterol and low-density lipoprotein levels has become a central objective in the effort to prevent cardiovascular events. Main body: Many guidelines were issued by different organizations and societies to define patient risk and establish important recommendations for management strategies. Newer cholesterol-lowering agents (non-statin drugs) are described, and their use is directed primarily to secondary prevention in patients at very high risk of new ASCVD. Conclusion: The present guidance summarizes the current methods for risk estimation and outlines the most recent data on lipid management in a simple user-friendly format, to improve physician awareness and help implement guidelines in the daily practice.
- 23 February 2021
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 73 (1) , 1-8
Open AccessEgyptian practical guidance in lipid management 2020
Background: Numerous epidemiological investigations and randomized clinical studies have determined that dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Consequently, the management of serum cholesterol and low-density lipoprotein levels has become a central objective in the effort to prevent cardiovascular events. Main body: Many guidelines were issued by different organizations and societies to define patient risk and establish important recommendations for management strategies. Newer cholesterol-lowering agents (non-statin drugs) are described, and their use is directed primarily to secondary prevention in patients at very high risk of new ASCVD. Conclusion: The present guidance summarizes the current methods for risk estimation and outlines the most recent data on lipid management in a simple user-friendly format, to improve physician awareness and help implement guidelines in the daily practice.